touchMEETING HIGHLIGHTS
Improving patient care in rare neuroimmunological disorders: clinical evidence and real-world experience with complement inhibition therapy
Overview
Anti-acetylcholine receptor antibody-positive (AChR-Ab+) generalised myasthenia gravis (gMG) and anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) are both rare autoimmune disorders, affecting the neuromuscular junction and central nervous system (CNS), respectively. Complement component 5 inhibitor therapy (C5IT) represents a targeted treatment approach for both AChR-Ab+ gMG and AQP4-Ab+ NMOSD, and works to block the complement cascade that contributes to tissue damage. In this activity, leading experts discuss updated clinical guidelines and patient-centric approaches to AChR-Ab+ gMG management, the role of complement in AQP4-Ab+ NMOSD pathophysiology, and review clinical and real-world evidence for C5IT therapy in AChR-Ab+ gMG and AQP4-Ab+ NMOSD.
Learning Objectives
After watching this activity, participants should be better able to:
- Understand the patient experience in AChR-Ab+ gMG, focusing on disease burden, disease management and treatment challenges
- Discuss treatment options supporting a patient-centric approach to care in patients with
AChR-Ab+ gMG - Review the role of the complement system in the pathophysiology of AQP4-Ab+ NMOSD
- Discuss efficacy and safety highlights from clinical experience and real-world evidence with complement component 5 inhibitor therapies
- Review considerations for initiating C5ITs and best practices from clinical experience in treating patients with C5ITs
- Review updated clinical guidelines for disease management in AChR-Ab+ gMG
Faculty information is available in the Toolkit.
Faculty information is available in the Toolkit.
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
